Living research guide
CADASIL research is active: gene-targeted therapies (exon-skipping, base editing, immunotherapy) are in preclinical development, and trials of cilostazol and stem-cell therapies are underway. This page tracks new findings and grades them honestly — promising, early, or unproven.
We monitor the literature so you don't have to, and we tell you plainly what's real. Nothing here is a cure yet — but the direction is genuinely hopeful, and connecting families to legitimate clinical trials is one of the most useful things we can do.
Common questions
- Is there promising CADASIL research?
- Yes — gene-targeted approaches (exon-skipping, base editing, immunotherapy) are in preclinical development, with cilostazol and stem-cell trials underway. None is FDA-approved yet.
Sources: PubMed; clinicaltrials.gov.
Evidence: Emerging
Last reviewed: July 2026.